Integrated Expression of Circulating miR375 and miR371 to Identify Teratoma and Active Germ Cell Malignancy Components in Malignant Germ Cell Tumors

Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study

(2019) Klaus-Peter Dieckmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum

(2019) Lucia Nappi et al.   JOURNAL OF CLINICAL ONCOLOGY

Serum MicroRNA-371a-3p Levels Predict Viable Germ Cell Tumor in Chemotherapy-naïve Patients Undergoing Retroperitoneal Lymph Node Dissection

(2019) John T. Lafin et al.   EUROPEAN UROLOGY

Serum Level of microRNA-375-3p Is Not a Reliable Biomarker of Teratoma

(2019) GAZANFER BELGE et al.   IN VIVO

Identification and Validation Model for Informative Liquid Biopsy-Based microRNA Biomarkers: Insights from Germ Cell Tumor In Vitro, In Vivo and Patient-Derived Data

(2019) João Lobo et al.   Cells

Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor

(2018) Ricardo Leão et al.   JOURNAL OF UROLOGY

Integrated Molecular Characterization of Testicular Germ Cell Tumors

(2018) Hui Shen et al.   Cell Reports

A pipeline to quantify serum and cerebrospinal fluid microRNAs for diagnosis and detection of relapse in paediatric malignant germ-cell tumours

(2015) Matthew J Murray et al.   BRITISH JOURNAL OF CANCER

Contemporary Management of Postchemotherapy Testis Cancer

(2012) Siamak Daneshmand et al.   EUROPEAN UROLOGY

MiRNAs and Cancer

(2009) Rosa Visone et al.   AMERICAN JOURNAL OF PATHOLOGY